{
    "data": [
        {
            "id": "4133415",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-22T05:33:37-05:00",
                "isLockedPro": false,
                "commentCount": 423,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's 2018 And Beyond - Buckle Up For A New Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "196006",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4133415-gileads-2018-and-beyond-buckle-up-for-new-gilead"
            }
        },
        {
            "id": "4132641",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-19T04:06:45-05:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Only Reason Why Gilead Might Not Buy Galapagos Straight Away",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "100666",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132641-only-reason-why-gilead-might-not-buy-galapagos-straight-away"
            }
        },
        {
            "id": "4132542",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-18T12:36:08-05:00",
                "isLockedPro": false,
                "commentCount": 129,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lessons From 2017: The Incomprehensible Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195847",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132542-lessons-from-2017-incomprehensible-gilead-sciences"
            }
        },
        {
            "id": "4132531",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-18T11:53:03-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What The Cell Design Labs Acquisition Means For Gilead?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195844",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132531-what-cell-design-labs-acquisition-means-for-gilead"
            }
        },
        {
            "id": "4132327",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-17T03:00:56-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - The Silver Bullet For NASH With Selonsertib And GS-9674 Combinations Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195803",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132327-gilead-sciences-silver-bullet-for-nash-selonsertib-and-gsminus-9674-combinations-treatment"
            }
        },
        {
            "id": "4132079",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-15T09:54:32-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Upcoming Conversation With An Expert: Highlights In CAR-T",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "100166",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132079-upcoming-conversation-expert-highlights-in-car-t"
            }
        },
        {
            "id": "4131946",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-14T15:37:55-05:00",
                "isLockedPro": false,
                "commentCount": 114,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Did ASH Just Change The Juno Best In Class Thesis?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195745",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4131946-ash-just-change-juno-best-in-class-thesis"
            }
        },
        {
            "id": "4131504",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-13T05:02:07-05:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - Brewing Stellar Molecule For NASH",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195671",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4131504-gilead-sciences-brewing-stellar-molecule-for-nash"
            }
        },
        {
            "id": "4131302",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-12T10:03:29-05:00",
                "isLockedPro": false,
                "commentCount": 167,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Avoid 2017's Frustrations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101887",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195638",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4131302-gilead-avoid-2017s-frustrations"
            }
        },
        {
            "id": "4131249",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-12T06:13:33-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead Remains Long-Term Story, Argenx Rallies, Bluebird Data",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4131249-your-daily-pharma-scoop-gilead-remains-long-term-story-argenx-rallies-bluebird-data"
            }
        },
        {
            "id": "4130921",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-10T18:14:21-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Doubles Down On CAR-T: Updates To Thesis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195559",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130921-gilead-doubles-down-on-car-t-updates-to-thesis"
            }
        },
        {
            "id": "4130769",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-08T16:32:32-05:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Going Down When It Should Go Up",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195536",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130769-gilead-sciences-going-down-when-should-go-up"
            }
        },
        {
            "id": "4130265",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-07T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130265-your-daily-pharma-scoop-gileads-potential-celgene-car-t-candidate-cellectar-soars"
            }
        },
        {
            "id": "4130162",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-06T14:33:06-05:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Wild Rollercoaster - Where Is It Heading?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130162-gileads-wild-rollercoaster-where-is-heading"
            }
        },
        {
            "id": "4128892",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-01T02:42:51-05:00",
                "isLockedPro": false,
                "commentCount": 143,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Integrated BioSci Research On Gilead Sciences - Why The Sovaldi China Expansion Will Deliver Gargantuan Growth?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195300",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4128892-integrated-biosci-research-on-gilead-sciences-why-sovaldi-china-expansion-will-deliver"
            }
        },
        {
            "id": "4128199",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-28T15:55:42-05:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead - Another Sobering Moment, But There Is More",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65393",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195181",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4128199-gilead-another-sobering-moment-is"
            }
        },
        {
            "id": "4127915",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-27T14:34:53-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Gilead Now And Get Kite For 'Free'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4127915-buy-gilead-now-and-get-kite-for-free"
            }
        },
        {
            "id": "4127827",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-27T11:06:54-05:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Are You Willing To Wait 3 Years?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4127827-gilead-sciences-are-you-willing-to-wait-3-years"
            }
        },
        {
            "id": "4127459",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-24T09:57:33-05:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Attractive After Big Retreat?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195038",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4127459-gilead-attractive-after-big-retreat"
            }
        },
        {
            "id": "4127291",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-23T01:10:35-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Integrated BioSci Research On Gilead Sciences: Promising Dividends And Favorable Valuations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195000",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4127291-integrated-biosci-research-on-gilead-sciences-promising-dividends-and-favorable-valuations"
            }
        },
        {
            "id": "4127114",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-22T09:56:04-05:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Buying New Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102603",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194966",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4127114-gilead-buying-new-growth"
            }
        },
        {
            "id": "4126248",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-19T13:53:03-05:00",
                "isLockedPro": false,
                "commentCount": 137,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Tapping Into The Vast China Market For Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194828",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4126248-gilead-sciences-tapping-vast-china-market-for-growth"
            }
        },
        {
            "id": "4125900",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-17T09:31:22-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4125900-your-daily-pharma-scoop-gilead-car-t-potential-egalet-surges-aerie-launches-mid-stage-study"
            }
        },
        {
            "id": "4125394",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-16T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 130,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Watch Out Gilead, Juno's Strategy Might Just Pay Off",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194733",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4125394-watch-out-gilead-junos-strategy-might-just-pay-off"
            }
        },
        {
            "id": "4125359",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-16T05:32:09-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How To Make Money With Gilead?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194728",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4125359-how-to-make-money-gilead"
            }
        },
        {
            "id": "4123777",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-12T02:48:30-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-vIgD",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194547",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4123777-integrated-biosci-research-on-gilead-sciences-hitting-next-growth-spurt-car-tcr-and-tip-vigd"
            }
        },
        {
            "id": "4122116",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-08T04:40:28-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Close But No Cigar For Our Gilead Sciences Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4122116-close-no-cigar-for-gilead-sciences-portfolio"
            }
        },
        {
            "id": "4118998",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-01T09:26:07-04:00",
                "isLockedPro": false,
                "commentCount": 225,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Is Persona Non Grata",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4118998-gilead-is-persona-non-grata"
            }
        },
        {
            "id": "4118367",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-31T05:44:58-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: More Of The Same, Long Thesis Holds",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194108",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4118367-gilead-sciences-of-long-thesis-holds"
            }
        },
        {
            "id": "4118091",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-30T12:04:14-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead's Unappreciated Opportunity, Merck's Keytruda Stumble, Epizyme's Positive Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4118091-your-daily-pharma-scoop-gileads-unappreciated-opportunity-mercks-keytruda-stumble-epizymes"
            }
        },
        {
            "id": "4117336",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-27T13:54:10-04:00",
                "isLockedPro": false,
                "commentCount": 210,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Bad News, Then The Good News, Then Some Guesses",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193996",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4117336-gilead-bad-news-good-news-guesses"
            }
        },
        {
            "id": "4117263",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-27T09:18:46-04:00",
                "isLockedPro": false,
                "commentCount": 134,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Declining Earnings Through 2019 (But 2020 Looks Great!)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4117263-gilead-declining-earnings-through-2019-2020-looks-great"
            }
        },
        {
            "id": "4117203",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-27T02:47:32-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Buy After Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4117203-gilead-buy-after-earnings"
            }
        },
        {
            "id": "4116946",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-26T16:06:02-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Sell Into Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4116946-gilead-sell-earnings"
            }
        },
        {
            "id": "4116846",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-26T13:08:59-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Dividend Growth Potential At A Reasonable Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22742",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4116846-gilead-sciences-dividend-growth-potential-reasonable-value"
            }
        },
        {
            "id": "4116372",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-25T14:57:48-04:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect From Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193913",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4116372-what-to-expect-from-gilead"
            }
        },
        {
            "id": "4114789",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T15:09:02-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What 'Yes' For Its CAR-T Therapy May Mean For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193736",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114789-what-yes-for-car-t-therapy-may-mean-for-gilead"
            }
        },
        {
            "id": "4114637",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T10:19:21-04:00",
                "isLockedPro": false,
                "commentCount": 134,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Turnaround Begins",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69905",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193721",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114637-gilead-turnaround-begins"
            }
        },
        {
            "id": "4114585",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T07:38:12-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead's Brave New World, AstraZeneca's Lynparza SNDA, Ignyta's Entrectinib Shows Positive Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114585-your-daily-pharma-scoop-gileads-brave-new-world-astrazenecas-lynparza-snda-ignytas"
            }
        },
        {
            "id": "4114530",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T02:17:48-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "FDA Approval Of Gilead CAR-T Therapy Will Move The Needle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114530-fda-approval-of-gilead-car-t-therapy-will-move-needle"
            }
        },
        {
            "id": "4114275",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T11:54:05-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Math Behind the Gilead's Recent Merger",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "91285",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114275-math-behind-gileads-recent-merger"
            }
        },
        {
            "id": "4114002",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-17T11:28:02-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Everybody's Gilead Problem, Halozyme's Further Progress, ZIOPHARM's Gene Therapy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114002-your-daily-pharma-scoop-everybodys-gilead-problem-halozymes-progress-ziopharms-gene-therapy"
            }
        },
        {
            "id": "4113727",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-16T12:11:52-04:00",
                "isLockedPro": false,
                "commentCount": 216,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: My Only 'Buy 'Til You Die' Investment, A Deep Due Diligence Dive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4113727-gilead-only-buy-til-you-die-investment-deep-due-diligence-dive"
            }
        },
        {
            "id": "4113055",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-12T07:30:07-04:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Biotech Continue To Boom?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102107",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193459",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4113055-will-biotech-continue-to-boom"
            }
        },
        {
            "id": "4112065",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-06T09:35:02-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead, Some History; Biogen's Spinraza, MDCO New Data, REPH Action Date",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4112065-your-daily-pharma-scoop-gilead-history-biogens-spinraza-mdco-new-data-reph-action-date"
            }
        },
        {
            "id": "4111876",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-05T12:30:22-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Time To Trust Gilead Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41741",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193242",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111876-time-to-trust-gilead-again"
            }
        },
        {
            "id": "4110214",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-28T11:27:12-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Buy Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102764",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192987",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4110214-3-reasons-to-buy-gilead"
            }
        },
        {
            "id": "4110203",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-28T11:23:23-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Spruces Itself Up With Large Target Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192984",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4110203-gilead-spruces-up-large-target-market"
            }
        },
        {
            "id": "4109658",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-26T17:48:06-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Premium Multiple With A Chinese Kicker",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192910",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109658-gileads-premium-multiple-chinese-kicker"
            }
        },
        {
            "id": "4109218",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-25T11:54:26-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Gilead At Mid-$80s, Keytruda's New Label, Ascendis's Positive Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109218-your-daily-pharma-scoop-gilead-mid-80s-keytrudas-new-label-ascendiss-positive-trial"
            }
        },
        {
            "id": "4108911",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-22T16:29:23-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why We Bought Gilead This Week",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192780",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4108911-why-bought-gilead-this-week"
            }
        },
        {
            "id": "4108294",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-20T13:25:29-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "March To Freedom Portfolio: Looking To Build Up Our Smaller Positions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "98446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4108294-march-to-freedom-portfolio-looking-to-build-up-smaller-positions"
            }
        },
        {
            "id": "4108234",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-20T09:03:33-04:00",
                "isLockedPro": false,
                "commentCount": 183,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead May Regain Growth Stock Status",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4108234-why-gilead-may-regain-growth-stock-status"
            }
        },
        {
            "id": "4106962",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-14T12:38:19-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Acquires Potential For Renewed Exponential Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4106962-gilead-acquires-potential-for-renewed-exponential-growth"
            }
        },
        {
            "id": "4106882",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-14T07:32:19-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Portfolio: Performance Update",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4106882-gilead-sciences-portfolio-performance-update"
            }
        },
        {
            "id": "4106693",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-13T16:40:43-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Kite-Gilead: Winners And Losers Part 2",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192428",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4106693-kite-gilead-winners-and-losers-part-2"
            }
        },
        {
            "id": "4105964",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-12T06:00:12-04:00",
                "isLockedPro": false,
                "commentCount": 131,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Poor Payback Period For Kite Pharma?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41891",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192334",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105964-gilead-poor-payback-period-for-kite-pharma"
            }
        },
        {
            "id": "4104140",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-05T11:09:42-04:00",
                "isLockedPro": false,
                "commentCount": 113,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How To Make 6% From Gilead In 40 Days",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4104140-how-to-make-6-percent-from-gilead-in-40-days"
            }
        },
        {
            "id": "4104048",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-05T04:01:30-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Acquisition Marks Major Sentiment Shift",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4104048-gilead-acquisition-marks-major-sentiment-shift"
            }
        },
        {
            "id": "4103709",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-01T15:07:47-04:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Plans To Acquire Kite Pharma Just Got Big-Time Validation From Novartis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21434",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192006",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103709-gileads-plans-to-acquire-kite-pharma-just-got-big-time-validation-from-novartis"
            }
        },
        {
            "id": "4103464",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T16:22:59-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Acquisition Of Kite Pharma Relieves Shareholders' Ennui",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103416",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191967",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103464-gileads-acquisition-of-kite-pharma-relieves-shareholders-ennui"
            }
        },
        {
            "id": "4103427",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T14:27:50-04:00",
                "isLockedPro": false,
                "commentCount": 216,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Let's Go Fly A Kite",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102327",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103427-gilead-go-fly-kite"
            }
        },
        {
            "id": "4103393",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T13:27:39-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Is Finally Flashing Buy Signals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102683",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103393-why-gilead-is-finally-flashing-buy-signals"
            }
        },
        {
            "id": "4103389",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T13:13:15-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Is Gilead On Fire?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191950",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103389-why-is-gilead-on-fire"
            }
        },
        {
            "id": "4103298",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T09:18:30-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences' Purchase Deal With Kite Pharma: Potential Scenarios And Associated Actions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102659",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4103298-gilead-sciences-purchase-deal-kite-pharma-potential-scenarios-and-associated-actions"
            }
        },
        {
            "id": "4103284",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-31T09:15:29-04:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Fairy-Tale Comeback",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103284-gileads-fairy-tale-comeback"
            }
        },
        {
            "id": "4103050",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-30T14:25:36-04:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead May Have Finally Bottomed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "96536",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191887",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103050-why-gilead-may-finally-bottomed"
            }
        },
        {
            "id": "4103019",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-30T13:18:12-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Inflection Point Achieved?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103019-gilead-sciences-inflection-point-achieved"
            }
        },
        {
            "id": "4102994",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-30T12:25:23-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Gilead Paid $12 Billion For $30 Million In Revenue And Thinks To Make A Profit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102994-how-gilead-paid-12-billion-for-30-million-in-revenue-and-thinks-to-make-profit"
            }
        },
        {
            "id": "4102974",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-30T10:51:45-04:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Kite-Gilead: Winners And Losers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102974-kite-gilead-winners-and-losers"
            }
        },
        {
            "id": "4102762",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T15:22:52-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And Kite: A Good Combination?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101681",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191843",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102762-gilead-and-kite-good-combination"
            }
        },
        {
            "id": "4102644",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T11:30:21-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Looks To Become The White Knight Of CAR-T",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191812",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102644-gilead-looks-to-become-white-knight-of-car-t"
            }
        },
        {
            "id": "4102591",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T08:01:17-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And Kite Pharma: The Game-Changing Acquisition We Have Been Waiting For",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191795",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102591-gilead-and-kite-pharma-game-changing-acquisition-waiting-for"
            }
        },
        {
            "id": "4102572",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T06:55:44-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Kite Cure",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102572-gilead-kite-cure"
            }
        },
        {
            "id": "4102564",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T06:22:33-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Finally Pulls The Trigger With $12-Billion Kite Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102564-gilead-finally-pulls-trigger-12-billion-kite-deal"
            }
        },
        {
            "id": "4102552",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T05:31:26-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Did Not Pay Too Much For Kite",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103073",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102552-gilead-not-pay-too-much-for-kite"
            }
        },
        {
            "id": "4102472",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-28T17:46:44-04:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Strong Buy At The Current Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "55342",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191773",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102472-gilead-strong-buy-current-price"
            }
        },
        {
            "id": "4102425",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-28T15:32:03-04:00",
                "isLockedPro": false,
                "commentCount": 232,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Thoughts On Gilead Trying To Fly With Kite",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191767",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102425-thoughts-on-gilead-trying-to-fly-kite"
            }
        },
        {
            "id": "4102418",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-28T15:17:20-04:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Acquisition Of The Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191765",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102418-gilead-sciences-acquisition-of-year"
            }
        },
        {
            "id": "4102370",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-28T13:06:32-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5 Reasons The Gilead-Kite Acquisition Might Work",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102370-5-reasons-gilead-kite-acquisition-might-work"
            }
        }
    ]
}